King: Ramipril not effective diabetes drug at three-year mark

By Elaine Rigoli

Tampa, Fla., Sept. 15 - King Pharmaceuticals, Inc. said the results of the Dream study (diabetes reduction assessment with ramipril and rosiglitazone medication study) suggested that although the incidence of the development of type 2 diabetes was lower overall among patients taking ramipril 15 mg compared to those taking a placebo (18.1% vs. 19.5%), the primary composite endpoint was not statistically different between ramipril and a placebo by the end of the three-year follow-up period.

Importantly, the company said the rates of development of diabetes began to diverge between the ramipril and placebo treatment groups beginning in the third year, with lower rates in the ramipril-treated group, suggesting that a longer follow-up period may have enabled detection of a significant ramipril treatment effect with respect to the composite primary endpoint.

However, the Bristol, Tenn., pharmaceutical company said ramipril demonstrated a favorable effect on blood pressure compared to a placebo, which suggests that a longer trial may detect benefits of ramipril on the incidence of new onset diabetes and cardiovascular morbidity.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.